|
|
Article: Positive Early Data Halting Herceptin Phase III Studies.
- Article from:
- BIOWORLD Today
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
West Coast Editor
With off-label use of Herceptin already slowly growing for early stage breast cancer patients, Genentech Inc. said two Phase III trials in that population were stopped after an interim analysis showed the drug offered benefit.
Genentech's stock (NYSE:DNA) closed Tuesday at $72.55, up $3.12, after trading as high as $75.50
Calling the company a "very conservative organization," analyst Eric Schmidt, with SG Cowen & Co. in New York, said the data "have got to be extremely clean" in order for Genentech to stop the trial.
Full data from the Herceptin studies, presented by the National Cancer Institute, won't be seen ...